Atopic dermatitis is the most common chronic inflammatory skin disease globally with huge socioeconomic implications, particularly in patients with moderate-to-severe disease. Atopic dermatitis commonly starts during the first year of life and affects over 200 million individuals worldwide, with estimated prevalence rates of up to 15–25% in children and 3–7% in adults. Some patients experience long-term resolution of their skin symptoms, whereas others have atopic dermatitis for their entire lives. The risk of persistence into adulthood is somewhat increased in individuals with later onset or a more severe atopic dermatitis course, but data differ greatly across studies. Despite an increased understanding of the pathogenesis of atopic dermatitis, there are no available biomarkers that can predict disease course. Although the traditional systemic therapeutics are broad-acting immunosuppressants with potentially deleterious long-term side-effects, novel, targeted agents have substantially broadened the therapeutic armamentarium. For decades, long-term disease control and maintenance were particularly challenging given that treatment options were limited to broad topical and systemic immunosuppressive agents.